GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Capex-to-Revenue

Sareum Holdings (LSE:SAR) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sareum Holdings's Capital Expenditure for the six months ended in Dec. 2023 was £0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was £0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Sareum Holdings Capex-to-Revenue Historical Data

The historical data trend for Sareum Holdings's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings Capex-to-Revenue Chart

Sareum Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.06 - - -

Sareum Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sareum Holdings's Capex-to-Revenue

For the Biotechnology subindustry, Sareum Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sareum Holdings's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sareum Holdings's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sareum Holdings's Capex-to-Revenue falls into.



Sareum Holdings Capex-to-Revenue Calculation

Sareum Holdings's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Sareum Holdings's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sareum Holdings  (LSE:SAR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Sareum Holdings Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sareum Holdings (LSE:SAR) Business Description

Traded in Other Exchanges
Address
Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.

Sareum Holdings (LSE:SAR) Headlines